These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1978520)

  • 1. Early dopamine agonist treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1990; 53():417-9. PubMed ID: 1978520
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug therapy of patients with early-stage parkinson's disease].
    Kondo T
    Nihon Rinsho; 2000 Oct; 58(10):2055-60. PubMed ID: 11068446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early combination of dopamine agonist and levodopa in the treatment of Parkinson's disease.
    Rinne UK
    Mt Sinai J Med; 1988 Mar; 55(2):138-41. PubMed ID: 3260342
    [No Abstract]   [Full Text] [Related]  

  • 4. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment of early Parkinson's disease: levodopa rehabilitated.
    Vlaar A; Hovestadt A; van Laar T; Bloem BR
    Pract Neurol; 2011 Jun; 11(3):145-52. PubMed ID: 21551108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

  • 7. [Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms].
    Goulley F; Wolmark Y; Bourdeix I; Chaumet-Riffaud PD
    Therapie; 1993; 48(3):233-8. PubMed ID: 7908147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.
    Avanzi M; Uber E; Bonfà F
    Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
    Wedekind S
    MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current approaches in the treatment of Parkinson disease].
    Caraceni T; Geminiani G; Tamma F
    Recenti Prog Med; 1989 Dec; 80(12):686-91. PubMed ID: 2576471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
    Olanow CW; Werner EG; Gauger LL
    Clin Neuropharmacol; 1989 Dec; 12(6):490-7. PubMed ID: 2575014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesulergine: a dopamine agonist with novel properties in Parkinson's disease.
    Lieberman AN; Gopinathan G; Pasternack P; Goldstein M
    Adv Neurol; 1990; 53():533-7. PubMed ID: 1978521
    [No Abstract]   [Full Text] [Related]  

  • 15. Early dopamine agonist therapy in Parkinson's disease.
    Rinne UK
    Mov Disord; 1989; 4 Suppl 1():S86-94. PubMed ID: 2566915
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 18. Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough.
    Montgomery EB
    Neurology; 2009 Jun; 72(24):2137; author reply 2137-8. PubMed ID: 19528526
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of levodopa-induced dyskinesia.
    Nutt JG
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S160-4; discussion S164-6. PubMed ID: 10762144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.